Cyclofenil in the treatment of scleroderma - a general view on the results after treating 29 cases.
Results are presented from an open treatment of 29 patients suffering from progressive systemic sclerosis (PSS) with cyclofenil, an oestrogenlike non-steroid compound with very low oestrogenicity, which was recently claimed to be effective in this disorder. The treatment resulted in significant improvement of the skin condition and regress of ulcerations, Raymaud's phenomenon, joint pain and stiffness. Most of the patients experienced an increased sense of well-being. A slight elevation of ASAT and ALAT was noted in seven patients and weight gain in two. Present data do not permit an assessment of whether the treatment might influence the visceral changes. A multi-centre controlled study is in progress.
D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D003408:Cresols / Q000627:therapeutic use*; D003506:Cyclofenil / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000201:enzymology; D013997:Time Factors
D003408:Cresols; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D003506:Cyclofenil